- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.01. | Amarin, Sarissa continue playing out activist attack | ||
| 19.01. | Off Editas' shelves, iNK cell therapies float to Shoreline | ||
| 19.01. | After hashing out comeback plans, Deciphera looks to raise $125M from stock sale | ||
| 19.01. | By summer solstice, we'll know the fate of Intercept's NASH drug | ||
| 19.01. | Horizon claims mid-stage victory in rare disease, lines up PhIII for new owners at Amgen | ||
| 19.01. | Ipsen has go/no-go decision to make after biotech partner's Parkinson's drug flunks PhIIb | ||
| 19.01. | Don't pack your sunglasses: No plans to move JP Morgan conference, bank says | ||
| 18.01. | Merck discovers 'root cause' of nitrosamine levels in blockbuster diabetes drugs | ||
| 18.01. | Sun Pharma picks 'Dr. Pimple Popper' for educational acne campaign | ||
| 18.01. | Amgen targets physicians with biosimilars education campaign in advance of expected 2023 breakout | ||
| 18.01. | FDA slaps Optum Infusion with a warning letter over 'insanitary' production conditions | ||
| 18.01. | Bristol Myers debuts first Opdualag campaign, adds to its two-combo cancer drug marketing | ||
| 18.01. | Drugmakers seek tweaks to FDA guidance on measuring development in pediatric trials | ||
| 18.01. | FDA+ roundup: Lessons learned from two quality ratings pilots; Expanded FDA collab with organ-on-a-chip company | ||
| 18.01. | FDA urges federal judge to protect abortion pill access | ||
| 18.01. | Amgen extends autoimmune pact with small Michigan biotech | ||
| 18.01. | Pathalys inks development deal with Abingworth company, raising $150M | ||
| 18.01. | Bluebird hopes to raise upwards of $100M by selling shares | ||
| 18.01. | J&J reports second HIV vaccine regimen failure in 18 months | ||
| 18.01. | Ex-US Commerce Secretary Wilbur Ross pairs his SPAC with Alzheimer's biotech | ||
| 18.01. | With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering | ||
| 18.01. | Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug | ||
| 18.01. | Gene therapy side effects prompt search for new delivery methods | ||
| 18.01. | Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies | ||
| 17.01. | Akili cuts about 30% of staff in effort to be 'extremely lean' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
